This page shows the latest Editas news and features for those working in and with pharma, biotech and healthcare.
Allergan and Editas Medicine have made history after scientists used a CRISPR treatment developed by the partners to edit cells inside the human body. ... treatment. Allergan and Editas plan to treat a further 18 LCA10 patients with EDIT-101, to evaluate
The first ever FDA-approved clinical trial of an in vivo CRISPR-based therapy is expected to get under way very soon; Editas and Allergan plan to begin the trial of
Companies developing other gene-editing technologies, such as CRISPR Therapeutics, Intellia Therapeutics and Editas Medicine, also saw their shares close down, suggesting a knee-jerk reaction in the sell-off.
Shares in company and competitors sink. Gene-editing specialist Editas Medicine will have to start its first CRISPR clinical trial without the direction of president and CEO Katrine Bosley, who has ... Editas has named board member Cynthia Collins as
But companies developing other gene-editing technologies, such as CRISPR Therapeutics, Intellia Therapeutics and Editas Medicine, also saw their shares close down which might suggest an element of panic in the
The Allergan team is excited to work with colleagues at Editas Medicine to develop EDIT-101 and potentially deliver a transformative medicine for LCA10 patients.". ... These developments have caused the shares of leaders in the field, CRISPR Therapeutics,
More from news
Approximately 3 fully matching, plus 6 partially matching documents found.
Editas, and the failure of Sangamo Therapeutics’ rival zinc-finger nucleases (ZFNs) platform. ... Editas, CRISPR, Sangamo, Cellectis/Allogene and their peers to take the slow road to proving that gene- editing can deliver safe and effective
There has been a lot of chatter about developing the tool for therapeutic use, and some specialised pharma companies such as Editas already have candidates in the pipeline. ... Editas Medicine and partner Allergan plan to initiate a phase 1/2 clinical
Editas Medicine has entered a strategic R&D alliance where Allergan has exclusive access to Editas’s CRISPR genome-editing programmes in ocular health, as well as options to license up ... 100. Editas. Allergan. R&D alliance. LCA10 and up to four other
This follows the $94m IPO of Editas Medicine in February this year.
companies. Other biotechs exploiting the CRISPR/Cas-9 technology for the development of therapeutics include Editas Medicine, Intellia Therapeutics and Caribou Biosciences; both Novartis and AstraZeneca have already developed collaborations in
More from intelligence
Approximately 0 fully matching, plus 6 partially matching documents found.
Most recently, Bosley served as the chief executive officer of Editas Medicine, and previously worked as CEO of Avila Therapeutics until its acquisition by Celgene.
He has previously served as CEO of Patheon. Genome editing company Editas Medicine has appointed James Mullen as chairman of the board of directors. ... Katrine Bosley, president and chief executive officer of Editas Medicine, said: “Jim is a renowned
Genome editing company Editas Medicine has strengthened its board of directors with the addition of Jessica Hopfield, who will also serve on the board's audit committee. ... She said: “I am honoured to join Editas Medicine’s board of directors. “
Alnylam Pharmaceuticals’ Dr Akshay Vaishnaw joins. Cambridge, Massachusetts-based Editas Medicine has appointed Dr Akshay Vaishnaw to its board of directors. ... Katrine Bosley, Editas Medicine's president and chief executive officer, said: “I am
More from appointments
Approximately 3 fully matching, plus 1 partially matching documents found.
We are the medical communications experts within McCann Health. Communicating science to bring meaning and positive change to people’s lives....